Belvarafenib

Belvarafenib is an orally available, type II pan-RAF kinase inhibitor that targets members of the Raf family of serine/threonine protein kinases, including mutant B-Raf (notably V600E), C-Raf (RAF1), and wild-type RAF dimers. It is designed to inhibit both monomeric and dimeric forms of mutant B-Raf proteins as well as wild-type RAF dimers. By blocking these kinases, belvarafenib disrupts the MAPK/ERK signaling pathway that drives cell proliferation and survival in cancers with RAS or RAF mutations. The drug has shown anti-tumor activity in preclinical models and early-phase clinical trials for advanced solid tumors—especially those harboring BRAF or NRAS mutations—including melanoma and other solid tumors with specific genetic alterations such as BRAF class II/III mutations or fusions. Belvarafenib is being developed by Hanmi Pharmaceutical and Genentech/Roche[1][3][4][5][6].

Other names

belvarafenib